2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process – High Priority Description: Percentage of patients aged 3 through 17 years, whoContinue reading “2025 #463 MIPS Measure Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)”
CQMS Archive
2025 #461 MIPS Measure Leg Pain After Lumbar Surgery
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient-Reported Outcome-Based Performance Measure – High Priority Description: For patients 18 years of ageContinue reading “2025 #461 MIPS Measure Leg Pain After Lumbar Surgery”
2025 #459 MIPS Measure Back Pain After Lumbar Surgery
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient-Reported Outcome-Based Performance Measure – High Priority Description: For patients 18 years of ageContinue reading “2025 #459 MIPS Measure Back Pain After Lumbar Surgery”
2025 #457 MIPS Measure Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days (lower score – better)
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process – High Priority Description: Percentage of patients who died from cancer, and admittedContinue reading “2025 #457 MIPS Measure Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days (lower score – better)”
2025 #453 MIPS Measure Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score – better)
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE:Process – High Priority Description: Percentage of patients who died from cancer receiving systemic cancer-directedContinue reading “2025 #453 MIPS Measure Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score – better)”
2025 #451 MIPS Measure RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Description: Percentage of adult patients (aged 18 or over) with metastatic colorectal cancerContinue reading “2025 #451 MIPS Measure RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy”
2025 #450 MIPS Measure Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE:Process – High Priority Description: Percentage of patients aged 18 to 70 with stage IContinue reading “2025 #450 MIPS Measure Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer”
2025 #448 MIPS Measure Appropriate Workup Prior to Endometrial Ablation
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process – High Priority Description: Percentage of patients, aged 18 years and older, whoContinue reading “2025 #448 MIPS Measure Appropriate Workup Prior to Endometrial Ablation”
2025 #445 MIPS Measure Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE:Outcome – High Priority Description: Percent of patients aged 18 years and older undergoing isolatedContinue reading “2025 #445 MIPS Measure Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)”
2025 #443 MIPS Measure Non-Recommended Cervical Cancer Screening in Adolescent Females
2025 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process – High Priority Description: The percentage of adolescent females 16–20 years of ageContinue reading “2025 #443 MIPS Measure Non-Recommended Cervical Cancer Screening in Adolescent Females”